Fig. 2From: Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)Kaplan–Meier estimates of the duration of response (A), progression-free survival (B), and overall survival (C)Back to article page